Transdermal drug delivery device and transdermal drug delivery equipment

Abstract

The utility model belongs to the technical field of medical instruments, and relates to a transdermal drug delivery device and transdermal drug delivery equipment. The application disc is provided with a central drug delivery cavity and a negative pressure outer ring cavity, the central drug delivery cavity can provide proper drug delivery temperature through heating, and the negative pressure outer ring cavity provides adsorption force to skin through connection with the host device. A temperature sensing element and an image sensor are further arranged on the application disc, so that more accurate temperature control and real-time monitoring of the skin state are achieved, and discomfort possibly occurring in the transdermal drug delivery process is avoided. After drug administration is completed, the main machine device can automatically relieve pressure so that the application disc can be taken down conveniently. According to the application, the safety and effectiveness of transdermal drug delivery are effectively improved.

Description

Technical Field

[0001] This utility model relates to the field of medical device technology, and in particular to a transdermal drug delivery device and transdermal drug delivery equipment. Background Technology

[0002] In the field of modern medicine, transdermal drug delivery has attracted much attention as a non-invasive treatment method, which can avoid the first-pass effect of oral drugs and reduce gastrointestinal irritation.

[0003] Some transdermal drug delivery devices have deficiencies in temperature control. Some lack heating functions, while others, even those with heating capabilities, lack precise temperature control. This can affect drug activity and absorption, and excessively high temperatures can burn the patient's skin, negatively impacting the user experience. Furthermore, the fixation method of the dressing is inadequate, making it prone to detachment under external force, hindering consistent and stable drug delivery. In addition, existing devices almost entirely lack features for achieving precise drug delivery. Utility Model Content

[0004] This application is made in view of the above-mentioned issues.

[0005] On the one hand, this application provides a transdermal drug delivery device.

[0006] The dressing tray includes a first top surface and a second top surface located at the top, a negative pressure outer ring cavity located at the bottom and opening downwards, and a central drug delivery cavity;

[0007] The negative pressure outer annular cavity includes a first top surface, a first annular outer wall, and a first annular inner wall;

[0008] The central drug delivery chamber includes a second top surface and a second annular wall, with the second annular wall flexibly connected to one end of the first annular inner wall via an annular bottom surface.

[0009] The central drug delivery chamber has a central protrusion, the top of which is flush with the edge of the lower opening of the dressing tray.

[0010] In some embodiments, the transdermal drug delivery device includes at least a drug pad placed in a central drug delivery chamber. The drug pad is circular in shape with a central through-hole and contains a volatile drug solution for treatment.

[0011] In some embodiments, a heating element and a first temperature sensing element are provided on the second top surface. The heating element is used to increase the drug delivery temperature of the central drug delivery chamber, and the first temperature sensing element is used to monitor the temperature of the heating element.

[0012] In some embodiments, an image sensor is disposed on the second top surface, the image sensor being used to acquire skin images.

[0013] In some embodiments, a second temperature-sensing element is provided at the top of the central protrusion for monitoring the skin surface temperature; the central protrusion matches the circular through hole in the center of the medicated pad for positioning and fixing the medicated pad.

[0014] In some embodiments, negative pressure unit walls are radially arranged on the negative pressure outer ring cavity, and the negative pressure unit walls, together with the first top surface, the first annular outer wall, and the first annular inner wall, constitute a plurality of independent negative pressure outer ring sub-cavities.

[0015] On the other hand, this application provides a transdermal drug delivery device.

[0016] It includes a main unit, a connecting device, and a transdermal drug delivery device, wherein the main unit and the transdermal drug delivery device are connected via the connecting device.

[0017] The main unit includes a control unit and at least one negative pressure unit.

[0018] The control unit controls the negative pressure unit to adjust the air pressure in a predetermined space within the transdermal drug delivery device via the connecting device;

[0019] The negative pressure unit is equipped with a pressure relief subunit. When the transdermal drug delivery treatment ends, the control unit controls the pressure relief subunit to release pressure in the predetermined space of the transdermal drug delivery device.

[0020] In some embodiments, the negative pressure unit is provided with a pressure sensor subunit, which is used to sense the pressure value of the predetermined space in the transdermal drug delivery device.

[0021] In some embodiments, the connection device includes a signal connection unit and at least one gas connection unit, the signal connection unit being used to transmit an electrical signal between the host device and the transdermal drug delivery device, and the gas connection unit being used to transmit gas between the host device and the transdermal drug delivery device.

[0022] The at least one technical solution adopted in this embodiment can achieve the following beneficial effects: the heating element, in conjunction with the first temperature sensing element and the second temperature sensing element, achieves precise control of the drug administration temperature, ensuring both drug activity and absorption, and effectively preventing skin burns during drug administration. The image sensor acquires skin images in real time, enabling timely detection of skin abnormalities during drug administration, and intelligent adjustment of drug administration parameters based on the analysis of these abnormalities. Through multiple independent negative pressure outer ring sub-cavities within the negative pressure outer ring cavity, the adsorption strength of each sub-cavity can be independently adjusted. Even if the airtightness of some sub-cavities decreases, the overall adsorption effect can be maintained by enhancing the adsorption force of other sub-cavities, ensuring a stable and continuous drug administration process. Attached Figure Description

[0023] To more clearly illustrate the technical solutions in the embodiments of this disclosure, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of this disclosure. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0024] Figure 1 This is a cross-sectional schematic diagram of the dressing plate of the transdermal drug delivery device according to an embodiment of this application;

[0025] Figure 2 This is a bottom view of the dressing tray of the transdermal drug delivery device according to an embodiment of this application;

[0026] Figure 3 This is a top view of the dressing tray of the transdermal drug delivery device according to an embodiment of this application;

[0027] Figure 4 This is a partial cross-sectional view of the dressing plate of the transdermal drug delivery device according to an embodiment of this application;

[0028] Figure 5 This is a partial cross-sectional view of the dressing plate of the transdermal drug delivery device according to an embodiment of this application;

[0029] Figure 6 This is a bottom view of the dressing tray of the transdermal drug delivery device according to an embodiment of this application;

[0030] Figure 7 This is a schematic diagram of a transdermal drug delivery device according to an embodiment of this application;

[0031] Figure 8 This is a structural block diagram of a transdermal drug delivery device according to an embodiment of this application;

[0032] Figure 9 This is a schematic flowchart of a method for using a transdermal drug delivery device according to an embodiment of this application.

[0033] Key component symbols: 1. Main unit; 2. Connecting device; 3. Transdermal drug delivery device; 4. Central drug delivery chamber; 5. Negative pressure outer ring chamber; 6. Drug pad; 7. First top surface; 8. First annular outer wall; 9. First annular inner wall; 10. Second top surface; 11. Annular bottom surface; 12. Second annular wall; 13. Heating element; 14. First temperature sensing element; 15. Second temperature sensing element; 16. Central protrusion; 17. Image sensor; 18. Gas connection unit; 19. Signal connection unit; 20. Negative pressure unit wall; 21. Negative pressure outer ring sub-cavity; 22. Gas connection hole. Detailed Implementation

[0034] To make the objectives, technical solutions, and advantages of this disclosure more apparent, exemplary embodiments according to this disclosure will now be described in detail with reference to the accompanying drawings. Obviously, the described embodiments are merely some embodiments of this disclosure, and not all embodiments of this disclosure. It should be understood that this disclosure is not limited to the exemplary embodiments described herein.

[0035] Figure 1 A cross-sectional schematic diagram of the dressing plate 3 of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is shown as an example.

[0036] like Figure 1 As shown, the dressing plate of the transdermal drug delivery device 3 includes: a central drug delivery chamber 4, a negative pressure outer ring chamber 5, an annular bottom surface 11, and a central protrusion 16.

[0037] The dressing tray is made of medical rubber material. It has a first top surface 7 and a second top surface 10 on the upper part, and a central drug delivery chamber 4 with an opening facing downward and a negative pressure outer ring chamber 5 on the lower part.

[0038] The central drug delivery chamber 4 is used to place a medicated pad 6 containing a volatile drug solution. A circular through-hole is provided at the center of the medicated pad 6. This circular through-hole and the central protrusion 16 located at the center of the central drug delivery chamber 4 allow the medicated pad 6 to be positioned and fixed within the central drug delivery chamber 4. The top of the central protrusion 16 is flush with the edge of the lower opening of the dressing plate. Besides positioning and fixing the medicated pad 6 in the central drug delivery chamber 4, it also helps maintain the distance between the skin and the heating element, preventing burns from high temperatures.

[0039] The negative pressure outer ring cavity 5 is connected to the negative pressure unit in the main unit 1 through the gas connection unit 18 in the connecting device 2. The air pressure difference between the air pressure in the negative pressure outer ring cavity 5 and the atmospheric pressure is formed by the air suction operation of the negative pressure unit. Due to the air pressure difference, the negative pressure outer ring cavity 5 is adsorbed onto the skin surface, so that the patch can be tightly attached to the skin.

[0040] The central drug delivery chamber 4 and the negative pressure outer ring chamber 5 are connected by an annular bottom surface 11. The annular bottom surface 11 enhances its ability to conform to the uneven parts of the skin through its own elastic deformation. At this time, the negative pressure outer ring chamber 5, the central drug delivery chamber 4 and the annular bottom surface 11 support each other and can deform independently, ensuring the adaptability of the dressing plate to the skin.

[0041] Figure 2 A bottom view schematic diagram of the dressing plate of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is shown as an example.

[0042] like Figure 2As shown, the first annular outer wall 8, the first annular inner wall 9, and the first top surface 7 form the negative pressure outer annular cavity 5, and the second annular wall 12 and the second top surface 10 form the central drug delivery cavity 4. The annular bottom surface 11 connects the negative pressure outer annular cavity 5 and the central drug delivery cavity 4. The annular bottom surface 11 is bendable, allowing the dressing plate to better adapt to the curvature of the skin. The three parts—the negative pressure outer annular cavity 5, the central drug delivery cavity 4, and the annular bottom surface 11—support each other and deform independently, improving the dressing plate's adaptability to uneven areas of the skin.

[0043] A gas communication hole 22 is provided on the negative pressure outer ring cavity 5, which is connected to the gas connection unit 18, for connecting the negative pressure outer ring cavity 5 and the gas connection unit 18.

[0044] At the top of the central protrusion 16, a second temperature sensing element 15 and an image sensor 17 are respectively disposed. The second temperature sensing element 15 is in close contact with the skin and is used to monitor the skin surface temperature during transdermal drug delivery treatment. The collected temperature data is transmitted to the host device 1. The image sensor 17 is used to acquire skin images in real time, then transmit the skin images to the host device 1, and analyze the acquired skin images based on computer vision algorithms to determine whether the skin is abnormal under transdermal drug delivery treatment.

[0045] Figure 3 A top view schematic diagram of the dressing plate of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is shown as an example.

[0046] like Figure 3 As shown, the connecting device 2 includes a gas connecting unit 18 and a signal connecting unit 19. The gas connecting unit 18 is connected to the negative pressure outer ring cavity 5. By drawing air from the negative pressure unit in the connected host device 1, the air pressure in the negative pressure outer ring cavity 5 is made lower than atmospheric pressure, thereby achieving the adsorption of the skin by the negative pressure outer ring cavity 5. The signal connecting device 2 is connected to the central drug delivery cavity 4, and transmits electrical signals to the electronic components in the central drug delivery cavity 4 through the host device 1.

[0047] Figure 4 A partial cross-sectional view of the negative pressure outer ring cavity 5 of the dressing plate of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is shown as an example.

[0048] like Figure 4 As shown, the gas connection unit 18 is connected to the negative pressure outer ring cavity 5. The negative pressure unit in the main unit 1 draws air from the negative pressure outer ring cavity 5 through the gas connection unit 18 in the connection device 2 to form a pressure difference with atmospheric pressure.

[0049] Figure 5 A partial cross-sectional view of the central drug delivery chamber 4 of the dressing plate of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is illustrated.

[0050] like Figure 5As shown, a second temperature sensing element 15 is provided at the top of the central protrusion 16. The second temperature sensing element 15 is in close contact with the skin and is used to monitor the skin surface temperature during transdermal drug delivery treatment. When the second temperature sensing element 15 detects that the skin surface temperature is higher than the preset upper limit, the main unit 1 issues an audible and visual alarm and automatically shuts down to avoid burns caused by excessively high skin temperature.

[0051] An image sensor 17 is also installed at the top of the central protrusion 16. The image sensor 17 is used to acquire skin images in real time, and then analyze the acquired skin images based on computer vision algorithms to determine whether adverse reactions such as allergies, redness, swelling, or ulceration have occurred. Once an abnormality is detected, the image sensor 17 immediately transmits the data to the host device 1. The host device 1 issues an alert to medical personnel through the display screen and simultaneously records the time, location, and severity of the abnormality. At the same time, the host device 1 will also intelligently adjust the drug administration parameters, including the drug administration time, drug administration temperature, and drug administration negative pressure, based on the analysis results of the skin images.

[0052] A heating element 13 is provided on the second top surface of the central drug delivery chamber 4. The main purpose of the heating element 13 is to heat the central drug delivery chamber 4, increase the drug delivery temperature, and ensure that the drug penetrates the skin at the optimal temperature. The heating element 13 operates under the control of the main unit 1.

[0053] A first temperature sensing element 14 is also provided on the second top surface of the central drug delivery chamber 4. The main purpose of the first temperature sensing element 14 is to monitor the temperature of the heating element 13 in real time and transmit the collected temperature data to the host device 1. The host device 1 dynamically adjusts the heating element 13 according to the preset temperature parameter range.

[0054] Specifically, the temperature data includes temperature data collected by the first temperature sensing element 14 and temperature data collected by the second temperature sensing element 15. When the temperature data collected by the first temperature sensing element 14 and / or the temperature data collected by the second temperature sensing element 15 approach a preset upper threshold, the main unit 1 automatically reduces the heating power of the heating element, so that the drug delivery temperature in the central drug delivery chamber 4 drops steadily; if the temperature data collected by the first temperature sensing element 14 and / or the temperature data collected by the second temperature sensing element 15 approach a preset lower threshold, the main unit 1 automatically increases the heating power of the heating element to ensure that the drug delivery temperature in the central drug delivery chamber 4 is always within the optimal range for drug penetration.

[0055] Figure 6 A bottom view of the dressing tray of the transdermal drug delivery device 3 according to an embodiment of the present disclosure is shown as an example.

[0056] like Figure 6As shown, a negative pressure unit wall 20 is provided in the negative pressure outer ring cavity 5. The negative pressure unit wall 20 is used to divide the negative pressure outer ring cavity 5 into several independent negative pressure outer ring sub-cavities 21. Each negative pressure outer ring sub-cavity 21 is provided with a gas connection hole 22. Each negative pressure outer ring sub-cavity 21 is connected to the corresponding negative pressure unit in the main unit 1 through its corresponding gas connection unit 18. The negative pressure unit can adjust the negative pressure value, so that the negative pressure value in each negative pressure outer ring sub-cavity 21 can be controlled independently. By independently controlling the negative pressure value of each negative pressure outer ring cavity 21, the adsorption force can be precisely adjusted according to the skin condition and treatment needs of different patients.

[0057] Furthermore, when the airtightness of part of the negative pressure outer ring cavity 21 decreases, the adsorption force can be enhanced by adjusting the negative pressure value in the remaining negative pressure outer ring cavity 21 to compensate for the reduced adsorption force due to the decrease in airtightness.

[0058] The annular bottom surface 11 is used to connect the negative pressure outer ring cavity 5 and the central drug delivery cavity 4. The negative pressure outer ring cavity 5 generates an adsorption force on the skin by constructing a pressure difference with the atmosphere. The central drug delivery cavity 4 uses a heated drug pad 6 to allow the active drug ingredient to be delivered transdermally at the optimal temperature to achieve the best transdermal drug delivery therapeutic effect.

[0059] A second temperature sensing element 15 is provided at the top of the central protrusion 16. When the dressing is in use, the second temperature sensing element 15 is in close contact with the skin to monitor the skin surface temperature during transdermal drug delivery treatment. The collected temperature data is transmitted to the host device 1 for drug delivery temperature control.

[0060] An image sensor 17 is installed at the top of the central protrusion 16. The image sensor 17 is used to acquire skin images in real time, and then analyze the acquired skin images based on computer vision algorithms to determine whether adverse reactions occur on the skin during drug administration.

[0061] Figure 7 A schematic diagram of a transdermal drug delivery device according to an embodiment of the present disclosure is illustrated. Figure 8 The present invention provides an exemplary structural block diagram of a transdermal drug delivery device according to an embodiment of the present disclosure.

[0062] like Figure 7 and Figure 8 As shown, the transdermal drug delivery device includes a main unit 1, a connecting device 2, and a transdermal drug delivery device 3.

[0063] like Figure 8As shown, the main unit 1 includes a control unit and at least one negative pressure unit. The negative pressure unit includes a pressure sensing subunit and a pressure relief subunit. The connecting device 2 includes a gas connection unit 18 and a signal connection unit 19. The main unit 1 and the transdermal drug delivery device 3 are connected via the connecting device 2. The transdermal drug delivery device 3 includes a central drug delivery chamber 4, a negative pressure outer ring chamber 5, an annular bottom surface 11, and a central protrusion 16.

[0064] The control unit is used to control the negative pressure unit in the main unit 1 and the electronic components in the dressing tray. Specifically, it is used to control the drug delivery temperature of the transdermal drug delivery device 3 and the negative pressure value of the negative pressure unit in the main unit 1.

[0065] The negative pressure unit adjusts the air pressure of the negative pressure outer ring cavity 5 in the transdermal drug delivery device 3 via the connecting device 2 to achieve a suitable adsorption force on the skin.

[0066] The negative pressure unit is equipped with a pressure relief subunit. When the transdermal drug delivery treatment ends, the control unit controls the pressure relief subunit to release the pressure of the negative pressure outer ring cavity 5 of the transdermal drug delivery device 3. After the pressure is released, the adhesion of the negative pressure outer ring cavity 5 to the skin is reduced, making it easier to remove the dressing.

[0067] Figure 9 An exemplary flowchart illustrating a method of using a transdermal drug delivery device according to an embodiment of the present disclosure is provided.

[0068] like Figure 9 As shown, it includes the following steps:

[0069] Step S901: Start the transdermal drug delivery device. The control unit in the main unit 1 initializes and checks whether the control unit and negative pressure unit are functioning normally. After confirming that they are normal, the control unit sends a command to the negative pressure unit to start it. The negative pressure unit draws gas from the outer negative pressure cavity 5 of the dressing plate through the gas connection unit 18 of the connection device 2. The air pressure in the outer negative pressure cavity 5 decreases, creating a pressure difference with the atmosphere and generating an adsorption force to achieve a tight fit between the dressing plate and the skin. During this process, the air pressure sensor subunit installed in the negative pressure unit senses the air pressure value in the outer negative pressure cavity 5 in real time through the connection unit. The collected data is transmitted to the control unit so that the control unit can adjust the adsorption force of the dressing plate as needed.

[0070] In step S902, after the dressing plate has finished adsorbing the skin, the control unit controls the heating unit inside the dressing plate to start working. The heating unit heats the drug pad 6 in the central drug delivery chamber 4. As the drug delivery temperature gradually heats up to the preset temperature, the activity and volatility of the effective drug components in the drug pad 6 are enhanced, ensuring the effectiveness of transdermal drug delivery treatment.

[0071] In step S903, the temperature sensing unit on the dressing plate collects the temperature of the heating unit and the patient's skin in real time. The collected temperature data is transmitted to the control unit, where it is analyzed. When the collected drug delivery temperature approaches the upper threshold, the control unit automatically reduces the power of the heating unit to lower the drug delivery temperature, thus preventing burns from excessive heat. When the collected drug delivery temperature approaches the lower threshold, the control unit automatically increases the power of the heating unit to raise the drug delivery temperature, ensuring the effectiveness of the drug delivery.

[0072] In step S904, the image sensor 17 on the dressing tray acquires skin images in real time at certain time intervals and transmits the skin image data to the host device 1 via the signal connection unit 19. The control unit in the host device 1 analyzes the acquired skin images based on computer vision algorithms such as YOLO, CNN, and ResNET to identify whether adverse reactions such as allergies, redness, swelling, or ulceration have occurred. If any abnormalities are detected, the control unit adjusts the drug administration parameters, including lowering the drug administration temperature, shortening the drug administration time, or reducing the drug administration negative pressure. If the situation is serious, the drug administration is stopped directly and an audible and visual alarm signal is issued to remind medical personnel to handle the situation promptly.

[0073] Step S905: After the preset drug administration treatment process is completed, the control unit in the main unit 1 controls the pressure relief subunit in the negative pressure unit to start working. When the pressure relief subunit is working, the outside air slowly enters the negative pressure outer ring cavity 5, the pressure difference between the air pressure in the negative pressure outer ring cavity 5 and the atmospheric pressure decreases, and the adhesion of the dressing to the skin slowly decreases. At this time, medical staff can easily remove the dressing.

[0074] The basic principles of this disclosure have been described above with reference to specific embodiments. However, it should be noted that the advantages, benefits, and effects mentioned in this disclosure are merely examples and not limitations, and should not be considered as essential features of each embodiment of this disclosure. Furthermore, the specific details disclosed above are for illustrative and facilitative purposes only, and are not limitations. These details do not limit the scope of this disclosure to the necessity of employing the aforementioned specific details for implementation.

[0075] The block diagrams of devices, apparatuses, devices, and systems disclosed herein are merely illustrative examples and are not intended to require or imply that they must be connected, arranged, or configured in the manner shown in the block diagrams. As those skilled in the art will recognize, these devices, apparatuses, devices, and systems can be connected, arranged, and configured in any manner. Words such as “comprising,” “including,” “having,” etc., are open-ended terms meaning “including but not limited to,” and are used interchangeably with them. The terms “or” and “and” as used herein refer to the terms “and / or,” and are used interchangeably with them unless the context clearly indicates otherwise. The term “such as” as used herein refers to the phrase “such as but not limited to,” and is used interchangeably with it.

[0076] Additionally, as used herein, the “or” used in a list of items beginning with “at least one” indicates a separate list, such that a list of, for example, “at least one of A, B, or C” means A or B or C, or AB or AC or BC, or ABC (i.e., A and B and C). Furthermore, the word “exemplary” does not imply that the described example is preferred or better than other examples.

[0077] It should also be noted that in the systems and methods of this disclosure, the components or steps can be decomposed and / or recombined. These decompositions and / or recombinations should be considered as equivalent solutions to this disclosure.

[0078] Various changes, substitutions, and modifications can be made to the technology described herein without departing from the teachings defined by the appended claims. Furthermore, the scope of the claims of this disclosure is not limited to the specific aspects of the processes, machines, manufactures, events, means, methods, and actions described above. Currently existing or later-developed processes, machines, manufactures, events, means, methods, or actions that perform substantially the same function or achieve substantially the same result as the corresponding aspects described above can be utilized. Therefore, the appended claims include such processes, machines, manufactures, events, means, methods, or actions within their scope.

[0079] The above description of the disclosed aspects is provided to enable any person skilled in the art to make or use this disclosure. Various modifications to these aspects will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other aspects without departing from the scope of this disclosure. Therefore, this disclosure is not intended to be limited to the aspects shown herein, but rather to be carried out within the widest scope consistent with the principles and novel features disclosed herein.

[0080] The above description has been given for purposes of illustration and description. Furthermore, this description is not intended to limit the embodiments of this disclosure to the forms disclosed herein. Although numerous exemplary aspects and embodiments have been discussed above, those skilled in the art will recognize certain variations, modifications, alterations, additions, and sub-combinations therein.

Claims

1. A transdermal drug delivery device, characterized in that, include: The dressing tray includes a first top surface and a second top surface located at the top, a negative pressure outer ring cavity located at the bottom and opening downwards, and a central drug delivery cavity; The negative pressure outer annular cavity includes a first top surface, a first annular outer wall, and a first annular inner wall; The central drug delivery chamber includes a second top surface and a second annular wall, with the second annular wall flexibly connected to one end of the first annular inner wall via an annular bottom surface. The central drug delivery chamber has a central protrusion, the top of which is flush with the edge of the lower opening of the dressing tray.

2. The transdermal drug delivery device as claimed in claim 1, characterized in that, It includes at least a medicated pad placed within the central drug delivery chamber. The medicated pad is circular in shape with a central through-hole and contains a volatile drug solution for treatment.

3. The transdermal drug delivery device as described in claim 1, characterized in that, A heating element and a first temperature sensing element are provided on the second top surface. The heating element is used to increase the drug delivery temperature of the central drug delivery chamber, and the first temperature sensing element is used to monitor the temperature of the heating element.

4. The transdermal drug delivery device as claimed in claim 1, characterized in that, An image sensor is provided on the second top surface, and the image sensor is used to acquire skin images.

5. The transdermal drug delivery device as claimed in claim 1, characterized in that, The top of the central protrusion is provided with a second temperature sensing element for monitoring the skin surface temperature; the central protrusion matches the circular through hole in the center of the medicated pad for positioning and fixing the medicated pad.

6. The transdermal drug delivery device according to any one of claims 1 to 5, characterized in that, The negative pressure outer ring cavity is radially provided with negative pressure unit walls, and the negative pressure unit walls, together with the first top surface, the first annular outer wall, and the first annular inner wall, constitute multiple independent negative pressure outer ring sub-cavities.

7. A transdermal drug delivery device, characterized in that, include: The main unit, the connecting device, and the transdermal drug delivery device as described in any one of claims 1 to 6, wherein the main unit and the transdermal drug delivery device are connected via the connecting device. The main unit includes a control unit and at least one negative pressure unit. The control unit controls the negative pressure unit to adjust the air pressure in a predetermined space within the transdermal drug delivery device via the connecting device; The negative pressure unit is equipped with a pressure relief subunit. When the transdermal drug delivery treatment ends, the control unit controls the pressure relief subunit to release pressure in the predetermined space of the transdermal drug delivery device.

8. The transdermal drug delivery device as described in claim 7, characterized in that, The negative pressure unit is equipped with a pressure sensor subunit, which is used to sense the pressure value of the predetermined space in the transdermal drug delivery device.

9. The transdermal drug delivery device as described in claim 7, characterized in that, The connection device includes a signal connection unit and at least one gas connection unit. The signal connection unit is used to transmit electrical signals between the host device and the transdermal drug delivery device, and the gas connection unit is used to transmit gas between the host device and the transdermal drug delivery device.

Images